We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker's (BRKR) Latest Workflows to Aid Applied Markets
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) recently highlighted its commitment to developing novel technology and improved mass spec workflows for applied markets at the 71st ASMS meeting. The company introduced a mass spectrometer, EVOQ DART-TQ+, the impact II VIP ESI-TOF (time of flight) system and TargetScreener 4D software.
The latest developments are expected to cater to the applied markets’ requirements of robustness, ease of use and the highest confidence in food/beverage, forensic/toxicology, industrial and environmental analysis.
More About the Recent Launches
Bruker’s unique triple-quad (TQ) mass spectrometer — EVOQ DART-TQ+ — is a high-performance workhorse that enables a straightforward routine analysis from simplified tuning and method development through data analysis and report generation for improved efficiency and productivity. The device features the first and fully integrated DART (Direct Analysis in Real Time) ionization source.
Image Source: Zacks Investment Research
The impact II VIP high-resolution QTOF mass spectrometer with the novel VIP-HESI source, is built on the proven reliability of the impact QTOF series. The new technical innovations enhance the sensitivity of the impact II VIP in Full-Sensitivity High-Resolution mode. The device is likely to deliver ultimate sensitivity for comprehensive screening and quantitation tasks.
Bruker implemented TargetScreener 4D, bringing the power of TIMS (trapped ion mobility spectrometry) to analyte screening and quantitation. Backed by more than 2,400 measured and predicted analyte CCS (collision cross section) values, TargetScreener 4D provides ultimate confidence in highly selective LC-TIMS-QTOF compound quantitation with even more reliable identification.
Per a representative at Bruker, with the world’s first fully integrated DART-TQ-MS system, the company is pioneering chromatography-free workflows for applied markets and point-of-need mass spec applications.
Industry Prospects
Per a Research report, the global mass spectrometry market size was valued at $5.26 billion in 2022 and is expected to witness a CAGR of 8.1% up to 2030.
Recent Developments
Earlier in May 2023, Bruker announced the completion of the acquisition of ZONTAL Inc. This buyout strengthens Bruker BioSpin’s Integrated Data Solutions software division, which includes Mestrelab Research, Arxspan and Optimal.
At the 2023 ENC (Experimental Nuclear Magnetic Resonance Conference) held in April, Bruker announced innovations for NMR spectroscopy in life science, pharma and cleantech research to enable discoveries in functional structural biology, drug discovery, and battery research.
Price Performance
In the past six months, Bruker has mostly outperformed its industry. Shares of BRKR have increased 10.3% against the industry’s decline of 11.3%.
Penumbra’s stock has risen 130% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has increased from $1.47 to $1.56 for 2023 and from $2.51 to $2.56 for 2024 in the past 30 days.
PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has increased from $4.98 to $5.60 in the past 30 days. Shares of the company have improved 25% in the past year against the industry’s 31.1% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Neuronetics’ loss per share have narrowed from $1.32 to $1.29 for 2023 in the past 30 days. Shares of the company have declined 12% in the past year compared with the industry’s 2.6% growth.
STIM’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.61%. In the last reported quarter, Neuronetics delivered an earnings surprise of 2.56%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Bruker's (BRKR) Latest Workflows to Aid Applied Markets
Bruker Corporation (BRKR - Free Report) recently highlighted its commitment to developing novel technology and improved mass spec workflows for applied markets at the 71st ASMS meeting. The company introduced a mass spectrometer, EVOQ DART-TQ+, the impact II VIP ESI-TOF (time of flight) system and TargetScreener 4D software.
The latest developments are expected to cater to the applied markets’ requirements of robustness, ease of use and the highest confidence in food/beverage, forensic/toxicology, industrial and environmental analysis.
More About the Recent Launches
Bruker’s unique triple-quad (TQ) mass spectrometer — EVOQ DART-TQ+ — is a high-performance workhorse that enables a straightforward routine analysis from simplified tuning and method development through data analysis and report generation for improved efficiency and productivity. The device features the first and fully integrated DART (Direct Analysis in Real Time) ionization source.
Image Source: Zacks Investment Research
The impact II VIP high-resolution QTOF mass spectrometer with the novel VIP-HESI source, is built on the proven reliability of the impact QTOF series. The new technical innovations enhance the sensitivity of the impact II VIP in Full-Sensitivity High-Resolution mode. The device is likely to deliver ultimate sensitivity for comprehensive screening and quantitation tasks.
Bruker implemented TargetScreener 4D, bringing the power of TIMS (trapped ion mobility spectrometry) to analyte screening and quantitation. Backed by more than 2,400 measured and predicted analyte CCS (collision cross section) values, TargetScreener 4D provides ultimate confidence in highly selective LC-TIMS-QTOF compound quantitation with even more reliable identification.
Per a representative at Bruker, with the world’s first fully integrated DART-TQ-MS system, the company is pioneering chromatography-free workflows for applied markets and point-of-need mass spec applications.
Industry Prospects
Per a Research report, the global mass spectrometry market size was valued at $5.26 billion in 2022 and is expected to witness a CAGR of 8.1% up to 2030.
Recent Developments
Earlier in May 2023, Bruker announced the completion of the acquisition of ZONTAL Inc. This buyout strengthens Bruker BioSpin’s Integrated Data Solutions software division, which includes Mestrelab Research, Arxspan and Optimal.
At the 2023 ENC (Experimental Nuclear Magnetic Resonance Conference) held in April, Bruker announced innovations for NMR spectroscopy in life science, pharma and cleantech research to enable discoveries in functional structural biology, drug discovery, and battery research.
Price Performance
In the past six months, Bruker has mostly outperformed its industry. Shares of BRKR have increased 10.3% against the industry’s decline of 11.3%.
Zacks Rank and Key Picks
Bruker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are Penumbra (PEN - Free Report) , Lantheus (LNTH - Free Report) and Neuronetics (STIM - Free Report) . While Penumbra and Lantheus each sport a Zacks Rank #1 (Strong Buy), Neuronetics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has risen 130% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has increased from $1.47 to $1.56 for 2023 and from $2.51 to $2.56 for 2024 in the past 30 days.
PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has increased from $4.98 to $5.60 in the past 30 days. Shares of the company have improved 25% in the past year against the industry’s 31.1% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Neuronetics’ loss per share have narrowed from $1.32 to $1.29 for 2023 in the past 30 days. Shares of the company have declined 12% in the past year compared with the industry’s 2.6% growth.
STIM’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.61%. In the last reported quarter, Neuronetics delivered an earnings surprise of 2.56%.